FDA seeks more data on Sarepta muscle disorder drug, shares slump

By Natalie Grover (Reuters) - Sarepta Therapeutics Inc suffered yet another setback after U.S. regulators asked for more data on its experimental muscle disorder drug, a move that further delays the marketing application for the treatment. Nearly a third of Sarepta's market value was wiped out on Monday after the company disclosed the U.S. Food and Drug Administration's decision on eteplirsen, its lead drug. ...

via Health News Headlines - Yahoo News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1rNsjgr